{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:44:59Z","timestamp":1761597899033,"version":"3.41.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673510","81703628"],"award-info":[{"award-number":["81673510","81703628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00228-018-2414-8","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T14:05:27Z","timestamp":1516111527000},"page":"583-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling"],"prefix":"10.1007","volume":"74","author":[{"given":"Shansen","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"issue":"Suppl 1","key":"2414_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/0883073897012001011","volume":"12","author":"JM Pellock","year":"1997","unstructured":"Pellock JM (1997) Lamotrigine. Lamotrigine J Child Neurol 12(Suppl 1):S1. https:\/\/doi.org\/10.1177\/0883073897012001011","journal-title":"Lamotrigine J Child Neurol"},{"issue":"3","key":"2414_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","volume":"25","author":"SI Johannessen","year":"2003","unstructured":"Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, Patsalos PN (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25(3):347\u2013363. https:\/\/doi.org\/10.1097\/00007691-200306000-00016","journal-title":"Ther Drug Monit"},{"issue":"11","key":"2414_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45(11):1061\u20131075. https:\/\/doi.org\/10.2165\/00003088-200645110-00002","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2414_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"A Rowland","year":"2006","unstructured":"Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34(6):1055\u20131062. https:\/\/doi.org\/10.1124\/dmd.106.009340","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"2414_CR5","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1177\/0883073897012001041","volume":"12","author":"WR Garnett","year":"1997","unstructured":"Garnett WR (1997) Lamotrigine: pharmacokinetics. J Child Neurol 12(Suppl 1):S10\u2013S15. https:\/\/doi.org\/10.1177\/0883073897012001041","journal-title":"J Child Neurol"},{"issue":"12","key":"2414_CR6","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2217\/pgs.11.105","volume":"12","author":"J Zhou","year":"2011","unstructured":"Zhou J, Argikar UA, Remmel RP (2011) Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics 12(12):1671\u20131679. https:\/\/doi.org\/10.2217\/pgs.11.105","journal-title":"Pharmacogenomics"},{"issue":"2","key":"2414_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e3181ceecc6","volume":"32","author":"SM Blanca","year":"2010","unstructured":"Blanca SM, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM, Nicolas JM, Adin J, Shushtarian M, Armijo JA (2010) UGT2B7\u2013161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 32(2):177\u2013184","journal-title":"Ther Drug Monit"},{"issue":"8","key":"2414_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","volume":"70","author":"Y Chang","year":"2014","unstructured":"Chang Y, Yang L-Y, Zhang M-C, Liu S-Y (2014) Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China. Eur J Clin Pharmacol 70(8):941\u2013946. https:\/\/doi.org\/10.1007\/s00228-014-1690-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"2414_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","volume":"71","author":"L Liu","year":"2015","unstructured":"Liu L, Zhao L, Wang Q, Qiu F, Wu X, Ma Y (2015) Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C\u2009>\u2009T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol 71(11):1341\u20131347. https:\/\/doi.org\/10.1007\/s00228-015-1925-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20132","key":"2414_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","volume":"95","author":"MI Gulcebi","year":"2011","unstructured":"Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95(1\u20132):1\u20138. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.01.016","journal-title":"Epilepsy Res"},{"issue":"6","key":"2414_CR11","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","volume":"69","author":"N Singkham","year":"2013","unstructured":"Singkham N, Towanabut S, Lertkachatarn S, Punyawudho B (2013) Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol 69(6):1285\u20131291. https:\/\/doi.org\/10.1007\/s00228-012-1449-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2414_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2710.2012.01351.x","volume":"37","author":"BB Brzakovic","year":"2012","unstructured":"Brzakovic BB, Vezmar KS, Vucicevic KM, Miljkovic BR, Martinovic ZJ, Pokrajac MV, Prostran MS (2012) Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. J Clin Pharm Ther 37(6):693\u2013697. https:\/\/doi.org\/10.1111\/j.1365-2710.2012.01351.x","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"2414_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.5414\/CPP47752","volume":"47","author":"JR Milovanovic","year":"2009","unstructured":"Milovanovic JR, Jankovic SM (2009) Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 47(12):752\u2013760. https:\/\/doi.org\/10.5414\/CPP47752","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"2414_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1177\/0091270007313391","volume":"48","author":"B Punyawudho","year":"2008","unstructured":"Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, Birnbaum AK (2008) Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 48(4):455\u2013463. https:\/\/doi.org\/10.1177\/0091270007313391","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2414_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/bcp.12984","volume":"82","author":"D Milosheska","year":"2016","unstructured":"Milosheska D, Lorber B, Vovk T, Kastelic M, Dol\u017ean V, Grabnar I (2016) Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol 82(2):399\u2013411. https:\/\/doi.org\/10.1111\/bcp.12984","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2414_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/00912709922007949","volume":"39","author":"TH Grasela","year":"1999","unstructured":"Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C (1999) Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 39(4):373\u2013384. https:\/\/doi.org\/10.1177\/00912709922007949","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2414_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1528-1167.2008.01866.x","volume":"50","author":"JJ Moeller","year":"2009","unstructured":"Moeller JJ, Rahey SR, Sadler RM (2009) Lamotrigine-valproic acid combination therapy for medically refractory epilepsy. Epilepsia 50(3):475\u2013479. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01866.x","journal-title":"Epilepsia"},{"issue":"4","key":"2414_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1212\/WNL.55.4.588","volume":"55","author":"AM Kanner","year":"2000","unstructured":"Kanner AM, Frey M (2000) Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 55(4):588\u2013591. https:\/\/doi.org\/10.1212\/WNL.55.4.588","journal-title":"Neurology"},{"issue":"9","key":"2414_CR19","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","volume":"62","author":"D Weintraub","year":"2005","unstructured":"Weintraub D, Buchsbaum R, Resor SJ, Hirsch LJ (2005) Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 62(9):1432\u20131436. https:\/\/doi.org\/10.1001\/archneur.62.9.1432","journal-title":"Arch Neurol"},{"issue":"4","key":"2414_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","volume":"83","author":"JY Chung","year":"2008","unstructured":"Chung JY, Cho JY, KS Y, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ (2008) Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83(4):595\u2013600. https:\/\/doi.org\/10.1038\/sj.clpt.6100324","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2414_CR21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","volume":"2","author":"V Biton","year":"2006","unstructured":"Biton V (2006) Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2(6):1009\u20131018. https:\/\/doi.org\/10.1517\/17425255.2.6.1009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"2414_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00228-016-2190-2","volume":"73","author":"Z-B Zhang","year":"2017","unstructured":"Zhang Z-B, Ji S-M, Han Y, Zang L-L, Wang Y-H, Lu W, Wang L, Wu Y (2017) Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy. Eur J Clin Pharmacol 73(4):445\u2013453. https:\/\/doi.org\/10.1007\/s00228-016-2190-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2414_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00228-013-1606-5","volume":"70","author":"B Brzakovi\u0107","year":"2014","unstructured":"Brzakovi\u0107 B, Vu\u010di\u0107evi\u0107 K, Kova\u010devi\u0107 SV, Miljkovi\u0107 B, Prostran M, Martinovi\u0107 \u017d, Pokrajac M (2014) Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients\u2014nonlinear mixed effects modelling approach. Eur J Clin Pharmacol 70(2):179\u2013185. https:\/\/doi.org\/10.1007\/s00228-013-1606-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2414_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00228-012-1311-9","volume":"69","author":"S Mallaysamy","year":"2013","unstructured":"Mallaysamy S, Johnson MG, Rao PGM, Rajakannan T, Bathala L, Arumugam K, van Hasselt JGC, Ramakrishna D (2013) Population pharmacokinetics of lamotrigine in Indian epileptic patients. Eur J Clin Pharmacol 69(1):43\u201352. https:\/\/doi.org\/10.1007\/s00228-012-1311-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2414_CR25","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","volume":"23","author":"V Chan","year":"2001","unstructured":"Chan V, Morris RG, Ilett KF, Tett SE (2001) Population pharmacokinetics of lamotrigine. Ther Drug Monit 23(6):630\u2013635. https:\/\/doi.org\/10.1097\/00007691-200112000-00006","journal-title":"Ther Drug Monit"},{"issue":"2","key":"2414_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1365-2125.2000.00237.x","volume":"50","author":"C Chen","year":"2000","unstructured":"Chen C (2000) Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. Br J Clin Pharmacol 50(2):135\u2013145. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00237.x","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"2414_CR27","doi-asserted-by":"publisher","first-page":"7763","DOI":"10.1007\/s11033-012-1615-y","volume":"39","author":"N Hakooz","year":"2012","unstructured":"Hakooz N, Alzubiedi S, Yousef AM, Arafat T, Dajani R, Ababneh N, Ismail S (2012) UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population. Mol Biol Rep 39(7):7763\u20137768. https:\/\/doi.org\/10.1007\/s11033-012-1615-y","journal-title":"Mol Biol Rep"},{"issue":"3","key":"2414_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clinbiochem.2006.01.002","volume":"39","author":"K Saito","year":"2006","unstructured":"Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A, Arimura Y, Imai K, Kurosawa N, Owada E, Miyamoto A (2006) Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 39(3):303\u2013308. https:\/\/doi.org\/10.1016\/j.clinbiochem.2006.01.002","journal-title":"Clin Biochem"},{"issue":"6","key":"2414_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A (2013) Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2(6):e50. https:\/\/doi.org\/10.1038\/psp.2013.24","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"2414_CR30","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/aps.2012.118","volume":"33","author":"DK He","year":"2012","unstructured":"He DK, Wang L, Qin J, Zhang S, Lu W, Li L, Zhang JM, Bao WQ, Song XQ, Liu HT (2012) Population pharmacokinetics of lamotrigine in Chinese children with epilepsy. Acta Pharmacol Sin 33(11):1417\u20131423. https:\/\/doi.org\/10.1038\/aps.2012.118","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"2414_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","volume":"54","author":"J Ding","year":"2015","unstructured":"Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z (2015) A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet 54(3):305\u2013317. https:\/\/doi.org\/10.1007\/s40262-014-0212-8","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"2414_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00228-005-0927-4","volume":"61","author":"CE Staatz","year":"2005","unstructured":"Staatz CE, Duffull SB, Kiberd B, Fraser AD, Tett SE (2005) Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol 61(7):507\u2013516. https:\/\/doi.org\/10.1007\/s00228-005-0927-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2414_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10928-008-9099-z","volume":"35","author":"K Tunblad","year":"2008","unstructured":"Tunblad K, Lindbom L, McFadyen L, Jonsson EN, Marshall S, Karlsson MO (2008) The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn 35(5):503\u2013526. https:\/\/doi.org\/10.1007\/s10928-008-9099-z","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"2414_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","volume":"33","author":"AF Meer van der","year":"2011","unstructured":"van der Meer AF, Marcus MA, Touw DJ, Proost JH, Neef C (2011) Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit 33(2):133\u2013146. https:\/\/doi.org\/10.1097\/FTD.0b013e31820f40f8","journal-title":"Ther Drug Monit"},{"issue":"5","key":"2414_CR35","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1345\/aph.17332","volume":"32","author":"GD Anderson","year":"1998","unstructured":"Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32(5):554\u2013563. https:\/\/doi.org\/10.1345\/aph.17332","journal-title":"Ann Pharmacother"},{"key":"2414_CR36","unstructured":"GlaxoSmithKline UK (2017) Summary of product characteristics for Lamictal. Available at http:\/\/www.medicines.org.uk\/emc\/medicine\/4228\/SPC\/Lamictal\/#FORM . Accessed 20 September 2017"},{"issue":"5","key":"2414_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","volume":"43","author":"Z Hussein","year":"1997","unstructured":"Hussein Z, Posner J (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43(5):457\u2013465. https:\/\/doi.org\/10.1046\/j.1365-2125.1997.00594.x","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2414_CR38","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","volume":"25","author":"B Rambeck","year":"1993","unstructured":"Rambeck B, Wolf P (1993) Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25(6):433\u2013443. https:\/\/doi.org\/10.2165\/00003088-199325060-00003","journal-title":"Clin Pharmacokinet"},{"issue":"5\u20136","key":"2414_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10928-005-0083-6","volume":"32","author":"JE Ahn","year":"2005","unstructured":"Ahn JE, Birnbaum AK, Brundage RC (2005) Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn 32(5\u20136):703\u2013718. https:\/\/doi.org\/10.1007\/s10928-005-0083-6","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2\u20133","key":"2414_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","volume":"57","author":"BE Gidal","year":"2003","unstructured":"Gidal BE, Sheth R, Parnell J, Maloney K, Sale M (2003) Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res 57(2\u20133):85\u201393. https:\/\/doi.org\/10.1016\/j.eplepsyres.2003.09.008","journal-title":"Epilepsy Res"},{"issue":"1","key":"2414_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0920-1211(00)00160-1","volume":"42","author":"BE Gidal","year":"2000","unstructured":"Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A (2000) Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res 42(1):23\u201331. https:\/\/doi.org\/10.1016\/S0920-1211(00)00160-1","journal-title":"Epilepsy Res"},{"issue":"3","key":"2414_CR42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0022-3565(25)11424-9","volume":"260","author":"J Magdalou","year":"1992","unstructured":"Magdalou J, Herber R, Bidault R, Siest G (1992) In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 260(3):1166\u20131173","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2414_CR43","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00228-016-2008-2","volume":"72","author":"K Inoue","year":"2016","unstructured":"Inoue K, Yamamoto Y, Suzuki E, Takahashi T, Umemura A, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K (2016) Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. Eur J Clin Pharmacol 72(5):555\u2013562. https:\/\/doi.org\/10.1007\/s00228-016-2008-2","journal-title":"Eur J Clin Pharmacol"},{"key":"2414_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fphar.2016.00437","volume":"7","author":"E Neumann","year":"2016","unstructured":"Neumann E, Mehboob H, Ramirez J, Mirkov S, Zhang M, Liu W (2016) Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol 7:437\u2013443","journal-title":"Front Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2414-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2414-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2414-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T21:46:49Z","timestamp":1751233609000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2414-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2414"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2414-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2018,1,16]]},"assertion":[{"value":"7 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients\u2019 guardians were informed about the purpose of the study, and the Shengjing Hospital ethics committee approved the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}